tiprankstipranks
CStone Pharmaceuticals to Unveil Promising Lymphoma Drug Data
Company Announcements

CStone Pharmaceuticals to Unveil Promising Lymphoma Drug Data

CStone Pharmaceuticals (HK:2616) has released an update.

Pick the best stocks and maximize your portfolio:

CStone Pharmaceuticals is set to present promising clinical data on its anti-ROR1 ADC, CS5001, for lymphoma at the upcoming American Society of Hematology Annual Meeting. This innovative drug has shown substantial anti-tumor activity, achieving an objective response rate of 43.5% in advanced B-cell lymphoma cases. As CStone continues to expand its global Phase I trial, investors and stakeholders should keep an eye on this potential breakthrough in cancer treatment.

For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App